ストックスクリーナーアプリを入手
18.10
1.74%
-0.32
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SRPT6155802 Latest News and Headlines - TradingView
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - MarketBeat
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
SRPT|Sarepta Therapeutics Inc|Price:17.890|Chg%:-0.530 - TradingKey
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta (SRPT) Q2 2026 Earnings Call Transcript - AOL.com
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - The National Law Review
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside - DirectorsTalk Interviews
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - Sahm
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A - TradingView
Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A - TradingView
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - Sahm
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
(SRPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
State Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - Stock Titan
Traders Purchase Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop - Sahm
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingView
Oppenheimer Adjusts PT on Sarepta Therapeutics to $35 From $37, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market - Streetwise Reports
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Q2 Earnings Call Highlights - MarketBeat
Is Sarepta Therapeutics Inc (SRPT) a Value Opportunity After Q2 Loss? GF Score: 63/100, Revenue at $401.3M - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highligh - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ... - Yahoo Finance
Sarepta Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SRPT) 2026-08-06 - Seeking Alpha
BlackRock, Inc. Adds to Sarepta Therapeutics Inc (SRPT) -- Shares Look 88% Undervalued on GF Value - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS - marketbeat.com
Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Sarepta beats Q2 2026 estimates as shares rise after hours - Investing.com
Sarepta rises on quarterly double-line beat - Seeking Alpha
Sarepta Therapeutics: Q2 Earnings Snapshot - Barchart.com
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q2 Adjusted EPS $0.64 per Share - marketscreener.com
Sarepta Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q2 Revenue $401.3M, vs. FactSet Est of $366.4M - marketscreener.com
Sarepta Therapeutics Inc. R (AB3A.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Sarepta Therapeutics 2Q 2026: Revenue $328.7M, EPS $(0.05) — 10-Q Summary - TradingView
Sarepta Therapeutics, Inc. Revises Revenue Guidance for the Year 2026 - marketscreener.com
Sarepta Therapeutics (NASDAQ: SRPT) swings to Q2 loss, details ELEVIDYS - Stock Titan
Sarepta Therapeutics Inc expected to post earnings of 26 cents a shareEarnings Preview - TradingView
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 49% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap? - Yahoo Finance
Vanguard Portfolio Management (SRPT) discloses 8.05% beneficial stake in Sarepta - Stock Titan
BlackRock (NYSE: BLK) discloses 16.6M-share Sarepta Therapeutics (SRPT) position in 13G/A - Stock Titan
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
ADAR1 Capital Management LLC Has $5.70 Million Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Leadership changes afoot at two CGT biotechs - Yahoo Finance
H.C. Wainwright reiterates Sarepta stock Sell rating on CEO transition By Investing.com - Investing.com Canada
Sarepta names Michael Severino, former Tessera CEO, as new chief executive - STAT
SRPT Looks 87.5% Undervalued on GF Value™ - GuruFocus
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):